Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Arterial Thrombosis in Factor V Leiden or Activated Protein C Resistance. Clinical and Experimental Studies.

  • Ellis Sampram
Publiceringsår: 2012
Språk: Engelska
Publikation/Tidskrift/Serie: Lund University, Faculty of Medicine Doctoral Dissertation Series
Volym: 2012:79
Dokumenttyp: Doktorsavhandling
Förlag: Clinical Coagulation Research Unit, Clinical Science, Malmö.



The last two decades has seen an avalanche of studies establishing Activated protein C (APC) resistance due to Factor V Leiden mutation as the most prevalent genetic risk factor, yet known, for venous thromboembolism. This has been documented in 20-60% of patients with deep vein thrombosis (DVT). Whether such propensity also exists in arterial circulation is still controversial. The general aim of the present thesis is to clearify some of the controversies that cloud the impact of APC resistance or Factor V leiden mutation on arterial thrombosis.

Paper I showed a significantly high prevalence of APC resistance or factor V Leiden mutation in peripheral vascular patients compared to the control group (22.7% vs 12.2%).

In Paper II, association between early occlusions of vascular reconstructions and Factor V Leiden mutation was shown. At one month, there was a two-fold risk of occlusion of vascular reconstructions compared to non-carriers (14% vs 7%, p=0.02). At one year, the same tendency was noted although not significant (22% vs 12%).

Paper III, an experimental arterial thrombosis study with factor V Leiden mice, revealed increased thrombogenicity in mice with Factor V Leiden mutation and arterial injury. There was a significant relationship between time to occlusion (TTO) and genotype (p=0.002). TTO was highest in the wild type mice (TTO: homozygote
Paper IV analyzing the mortality, amputation rate and inflammatory mediators in critical limb ischemia (CLI) patients with Factor V Leiden did not find any significant difference in inflammatory mediators between critical limb ischemia patients with Factor V Leiden and non-carriers. There was neither a significant difference in the rate of amputation at one year nor mortality up to 10 years between CLI patients with FVL mutation and non-carriers.

Conlusions: Resistance to activated protein C or Factor V Leiden mutation is more prevalent in patients with peripheral vascular diseases than the general population, the risk for early occlusions of vascular reconstructions increases two-folds in FVL patients compared to non-carriers and FVL enhances arterial thrombosis development after vessel wall injury in experimental FVL mice. However, no difference in long-term (10 years) mortality or one-year amputation rate is seen between critical limb ischemia patients with FVL mutation and non-carriers.


Waldenströmssalen, Jan Waldenströmsgatan 14, Skanes University Hospital, Malmö. Sweden
  • Tomas Lindahl (Professor)


  • Cardiac and Cardiovascular Systems
  • Activated protein c resistance
  • Factor V Leiden mutation
  • thrombophilia
  • hypercoagulable state
  • Factor V Leiden mice
  • arterial thrombosis
  • venous thromboembolism
  • peripheral vascular reconstructions
  • peripheral vascular reconstruction occlusion


  • Clinical Coagulation, Malmö
  • Peter Svensson
  • Bengt Lindblad
  • ISSN: 1652-8220
  • ISBN: 978-91-87189-42-5

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at]

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen